NPI | Name | Type | Address |
---|---|---|---|
MR. RPH Robert Kelly Hansen |
Individual |
514 Peregrine Cv Layton, UT |
|
DR. PHARMD Kristen Smith Vinik |
Individual |
50 N Medical Dr Pharmacy Room A050 Salt Lake City, UT |
|
DR. PHARMD Shauna Brooke Burns |
Individual |
1950 Circle Of Hope Dr Pharmacy Services Salt Lake City, UT |
|
PHARMD Thu M Tran |
Individual |
1950 Circle Of Hope Dr Suite 2110, Pharmacy Services Salt Lake City, UT |
|
PHARM.D. Lisa Annette Cox |
Individual |
2000 Circle Of Hope Dr Suite 2440 Salt Lake City, UT |
|
PHARMD Patricia Ann Jeppson |
Individual |
1950 Circle Of Hope Dr Ste 2110 Salt Lake City, UT |
|
DR. PHARM. D Daniel Sageser |
Individual |
1950 Circle Of Hope Dr Suite 2110 Salt Lake City, UT |
|
DR. PHARMD Jeffrey Gilreath |
Individual |
1950 Circle Of Hope Dr Salt Lake City, UT |
|
MR. RPH, MS Scott B Silverstein |
Individual |
1950 Circle Of Hope Dr Ste 2110p Salt Lake City, UT |
|
DR. PHARM.D., BCOP Christine Louise Crossno |
Individual |
2000 Circle Of Hope Dr Huntsman Cancer Institute, Dept Of Pharmacy Salt Lake City, UT |
|
DR. PHARMD Steven Lee Kirkegaard |
Individual |
2000 Circle Of Hope Dr Ste 2440 Salt Lake City, UT |
|
DR. PHARMD Courtney C Cavalieri |
Individual |
2000 Circle Of Hope Dr Salt Lake City, UT |
|
PHARMD Megan Mullalley |
Individual |
4393 S Riverboat Rd Taylorsville, UT |
|
DR. PHARMD Michael Lloyd Reeder |
Individual |
5121 S Cottonwood St Murray, UT |
|
Gmt Pharmacy Pc |
Organization |
1890 S 3850 W Ste 220a Salt Lake City, UT |
Every health care provider, whether it’s a hospital, pharmacy, or individual specialist, must obtain their own NPI number. This identification number is unique and is assigned upon application. In tod...
Taxonomy Code | 1835X0200X |
Specialization | Oncology |
Display Name | Oncology Pharmacist |
Taxonomy Group | Pharmacy Service Providers |
Taxonomy Classification | Pharmacist |
Definition | A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases. |
Effective Date | September 30, 2009 |